1. A new journal, cancer immunology and immunotherapy

   EditorialNotes Pages: 1 - 2

2. Surviving in company of BCG

   • G. Mathé

   Editorial Pages: 3 - 5

3. Experimental basis of BCG systemic immunotherapy

   • I. Florentin

   Short Review Pages: 7 - 9

4. Preservation of fresh BCG scarification vaccine at 4, −25, and −70° C

   • M. Gheorghiu
   • L. Chambon

   Original Articles Pages: 11 - 16

5. Comparison of various BCG preparations in the EORTC — ICIG experimental screening for systemic immunity adjuvants applicable to cancer immunotherapy

   • O. Halle-Pannenko
   • Ch. Bourut
   • M. Kamel

   Original Articles Pages: 17 - 23

6. Antitumor activity and other biological properties of two phenotypes isolated from BCG

   • R. Turcotte
   • M. Quevillon

   Original Articles Pages: 25 - 30

7. Studies on the mechanisms of action of BCG

   • I. Florentin
   • R. Huchet
   • G. Mathé

   Original Articles Pages: 31 - 39

8. Enhancement of T suppressor activity in mice by high doses of BCG

   • M. Geffard
   • S. Orbach-Arbouys

   Original Articles Pages: 41 - 43

9. The immunoproliferative response of mice to intravenously or subcutaneously injected BCG

   • H. Rappaport
   • A. Khalil

   Original Articles Pages: 45 - 49

10. BCG and the specific immune response to tumor

    • I. B. Parr

    Original Articles Pages: 51 - 53

11. Toxicity studies of intravenously administered BCG in baboons

    • S. Jurczyk-Procyk
    • M. Martin
    • H. Rappaport

    Original Articles Pages: 55 - 61

12. Toxic effects of massive doses of BCG in mice, guinea pigs, and monkeys

    • V. Portelance
    • M. Quevillon
    • Y. Page

    Original Articles Pages: 63 - 67

13. Human toxicology of BCG applied in cancer immunotherapy

    • L. Schwarzenberg
    • M. C. Simmler
    • J. L. Pico

    Original Articles Pages: 69 - 76

14. 1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy

    • G. Mathe
    • F. de Vassal
    • C. Jasmin

    Original Articles Pages: 77 - 86

15. Various uses of BCG and allogeneic acute leukemia cells to treat patients with acute myelogenous leukemia

    • J. A. Russell
    • B. Chapuis
    • R. L. Powles

    Original Articles Pages: 87 - 91

16. Present status of BCG immunotherapy of malignant melanoma

    • D. L. Morton
    • F. R. Eilber
    • K. P. Ramming

    Original Articles Pages: 93 - 98

17. Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival

    • J. U. Gutterman
    • G. M. Mavligit
    • E. M. Hersh

    Original Articles Pages: 99 - 107

18. BCG in the immunotherapy of Hodgkin's disease and non-Hodgkin's lymphomas

    • B. Hœrni
    • J. Chauvergne
    • C. Lagarde

    Short Communication Pages: 109 - 112

19. Increase of null cells in patients submitted to long-term active immunotherapy

    • D. Belpomme
    • R. Joseph
    • N. Lelarge

    Letter To CII Pages: 113 - 114